Bao Quanying, Jog Rajan, Shen Jie, Newman Bryan, Wang Yan, Choi Stephanie, Burgess Diane J
University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA.
FDA/CDER, Office of Generic Drugs, Office of Research and Standards, Division of Therapeutic Performance, Silver Spring, MD 20993, USA.
Int J Pharm. 2017 May 15;523(1):310-319. doi: 10.1016/j.ijpharm.2017.03.039. Epub 2017 Mar 24.
The investigation of semisolid ophthalmic ointments is challenging due to their complex physicochemical properties and the unique anatomy of the human eye. Using Lotemax as a model ophthalmic ointment, three different manufacturing processes and two excipient sources (Fisher (OWP) and Fougera (NWP)) were used to prepare loteprednol etabonate ointments that were qualitatively and quantitatively the same across the manufactured formulations. Physicochemical properties including drug content and uniformity, particle size and distribution, as well as rheological parameters (onset point, crossover modulus, storage modulus and Power law consistency index) were investigated. In addition, USP apparatus 2 with enhancer cells was utilized to study the in vitro drug release characteristics of the ophthalmic ointments. Both manufacturing processes and excipient sources had a significant influence on the physicochemical attributes and the in vitro drug release profiles of the prepared ointments. Ointments prepared via the hot melt processes exhibited higher rheological parameters and lower drug release rates compared to ointments prepared without hot melting. Ointments prepared with OWP demonstrated higher rheological parameters and lower in vitro drug release rates compared to ointments prepared with NWP. A strong correlation between the rheological parameters and in vitro drug release rate was shown using logarithmic linear regression. This correlation may be useful in predicting in vitro drug release from measured physicochemical properties, and identifying the critical quality attributes during the development of ointment formulations.
由于半固体眼用软膏复杂的物理化学性质以及人眼独特的解剖结构,对半固体眼用软膏进行研究具有挑战性。以氯替泼诺妥布霉素眼膏作为模型眼用软膏,采用三种不同的制造工艺和两种辅料来源(Fisher(OWP)和Fougera(NWP))制备氯替泼诺妥布霉素眼膏,这些眼膏在整个制造配方中在定性和定量上都是相同的。研究了包括药物含量和均匀性、粒度和分布以及流变学参数(起始点、交叉模量、储能模量和幂律稠度指数)在内的物理化学性质。此外,使用带有增强细胞的美国药典装置2来研究眼用软膏的体外药物释放特性。制造工艺和辅料来源对所制备软膏的物理化学属性和体外药物释放曲线均有显著影响。与未热熔制备的软膏相比,通过热熔工艺制备的软膏表现出更高的流变学参数和更低的药物释放速率。与用NWP制备的软膏相比,用OWP制备的软膏表现出更高的流变学参数和更低的体外药物释放速率。使用对数线性回归显示流变学参数与体外药物释放速率之间存在强相关性。这种相关性可能有助于从测量的物理化学性质预测体外药物释放,并在软膏制剂开发过程中识别关键质量属性。